Samsung Biologics launches 3 trillion won rights issue

Samsung Biologics announced a KR 3 trillion rights offering aimed at financing a three‑dimensional growth plan that includes capacity upgrades, portfolio diversification and geographic reach.

Details of the rights offering and pricing

The firm will issue about 2,270,000 new common shares at KRW 1,322,000 each, roughly a 15 % discount to the reference price. The total amount sought represents about 4.9 % of the company’s market value based on the prior day’s close. Existing shareholders receive the allocation on a pro‑rata basis, with any leftovers sold to the public.

Under Korea’s Capital Markets Act, 20 % of the new shares go to the employee stock ownership association; the balance is offered to shareholders proportionally. Those who decline can trade their subscription rights on the market, and any unsold shares will be taken up by the lead underwriter.

Planned use of proceeds and expansion outlook

Approximately KRW 2.71 trillion is earmarked for the all‑cash acquisition of PolyPeptide Group, a Swiss‑based developer of peptide therapeutics. The remaining KRW 290 billion will fund the next phase of Bio Campus II, slated to follow the completion of Plant 5 in 2025.

After Plant 5, the firm is reviewing the sequential launch of Plants 6 through 8, a move that would lift global manufacturing capacity to 1,385,000 liters by 2032. This scale‑up would broaden the service portfolio beyond antibodies and antibody‑drug conjugates to include peptide‑based drugs, reflecting rising demand for varied modalities.

The rights offering timeline runs from September 30, when the securities registration becomes effective, to a November 9‑10 subscription window for existing shareholders. A public offering follows on November 12‑13, with new shares slated for listing on November 30.

John Rim, President and CEO, said, “Building on our position as a global top‑tier CDMO, this capital raise sets the stage for our next phase of growth.” He added confidence that the acquisition and campus expansion will deepen leadership and create lasting shareholder value.

The paperwork felt oddly like a maze of forms, but the financial mechanics are straightforward: a rights issue, a discount, and a clear split between acquisition and plant development funds.

Historically, the firm’s earlier capacity expansions required similar capital raises, yet those moves focused solely on antibody production. By contrast, this combined approach—adding peptide expertise while enlarging physical capacity—mirrors a broader industry trend where manufacturers seek to hedge against modality‑specific market swings.

When the new shares list, the market will see a modest dilution of roughly 5 % of existing equity, a level that analysts typically view as manageable given the projected revenue uplift from the expanded service slate.